Genflow Biosciences in focus as longevity research expands into animal health

Genflow Biosciences Plc

Genflow Biosciences highlights the growing commercial interest in longevity science as research into extending healthy lifespan expands beyond human medicine to include companion animals.

The growing interest in animal longevity could create opportunities for biotechnology companies working on the biological mechanisms of ageing. Genflow Biosciences is focused on longevity science, including research into the SIRT6 gene and its potential role in healthy ageing. However, the animal longevity developments discussed here should not be interpreted as evidence that Genflow has a canine treatment or programme.

The emerging animal longevity sector is attracting researchers and businesses interested in whether scientific advances could help pets live longer, healthier lives. Dogs are a particular focus because their ageing process can be studied over a shorter period than human ageing, potentially allowing researchers to assess interventions and their effects on age-related changes.

For Genflow, the wider interest in longevity research provides context for its work on ageing biology. The company’s approach centres on SIRT6, a gene associated with DNA repair, genome stability and metabolic regulation. Research into these processes is part of a broader effort to understand why organisms age and whether biological mechanisms linked to ageing can be targeted therapeutically.

The commercial potential of longevity science depends on translating early research into safe and effective treatments. Animal longevity research may offer opportunities for veterinary medicine, but it remains a distinct field with its own regulatory requirements, clinical evidence and commercial considerations. Results from animal studies cannot automatically be applied to humans, nor can findings from human-focused research be assumed to translate into treatments for dogs.

Genflow Biosciences plc (LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Genflow Biosciences in focus as longevity research expands into animal health

Longevity research is expanding into animal health, while Genflow Biosciences continues to focus on the potential of SIRT6-related science...

Pet food industry turns to healthy ageing as demand for longevity products grows

Growing interest in pet longevity is creating opportunities for specialised nutrition, supplements and veterinary treatments. Improved research into the...

Genflow Biosciences CEO Dr Eric Leire discusses SIRT6 gene therapy results in aged dogs

Genflow Biosciences CEO Dr Eric Leire discusses interim SLAB-VET trial results, the potential of SIRT6 gene therapy in ageing...

Genflow reports biological age reductions in dog gene therapy study

Genflow Biosciences reports reductions in measured epigenetic age in dogs receiving SIRT6c gene therapy, selecting intravenous plasmid DNA as...

Genflow Biosciences secures Japanese patent and expands animal health partnerships

Genflow Biosciences has secured Japanese patent allowance for its SIRT6 gene therapy, with all 16 claims approved, and signed...

Genflow Biosciences: SLAB-VET Results Put SIRT6 Partnering and Human Therapies in Focus (video)

Genflow Biosciences’ latest SLAB-VET-001 results are sharpening the commercial case for its SIRT6c platform. CEO Dr Eric Leire discusses...

Search